drugset / Trial / NCT00226421

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

NCT00226421

Phase 3 Completed 120 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.

Timeline

Start
2004-10
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymorphone Small molecule Oral

Indications